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LETTER TO THE EDITOR
Unusual effectiveness of systemic
steroids in Whipple diseaseF
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therapy  with  1.5  mg/kg  of  methylprednisolone  was  started
and  a rapid  clinical  improvement  with  a  parallel  resolutionTo  the  Editor,
Whipple’s  disease  is  a  rare  disorder  caused  by  the  Gram-
positive  bacterium  Tropheryma  whipplei  (TW),  formerly
known  as  Tropheryma  whippelii,  that  localizes  initially  in  the
lamina  propria  of  small  bowel  with  prominent  gastrointesti-
nal  symptoms  and  weight  loss.1 However,  it  can  also  cause
a  wide  range  of  clinical  manifestations,  due  to  its  spread-
ing  to  other  sites  (i.e.  endocardium,  lymph  nodes,  central
neurologic  system,  serum  membranes)2 including  pulmonary
manifestations.3,4
We  draw  here  to  attention  a  quite  unique  case  of  Whipple
disease  complicated  by  lung  involvement  probably  due  to  an
immune  reconstitution  syndrome.
This  refers  to  a  caucasian  77-year-old  man  diagnosed  with
Whipple’s  disease  in  2015  (relapsed  in  2018)  treated  with
doxycycline  and  hydroxychloroquine  then  withheld  because
of  gastrointestinal  intolerance.  In  the  past  medical  history,
he  was  diagnosed  with  a  type  1  myelomonocytic  chronic
leukemia,  peripheral  axonal  neuropathy,  dermatitis  due  to
a  possible  immune  reconstitution  syndrome,  osteoporosis
due  to  steroid  therapy  treated  with  vertebroplasty,  hyper-
tension,  aortic  insufficiency,  bilateral  glaucoma,  benign
prostatic  hypertrophy  and  intestinal-type  gastric  adenocar-
cinoma  treated  with  endoscopic  resection  in  2019.
He  was  admitted  on  September  2019  to  the  emer-
gency  room  due  to  high  fever  the  night  before,  thoracalgia
and  arterial  blood  gases  abnormalities  (pO2  58  mmHg,
pCO2  29  mmHg,  pH  7.45);  chest  X-ray  documented  lung
involvement  with  pleural  effusion  (Fig.  1).  Vital  parame-
ters  indicated  mild  hypotension  (90/50  mmHg),  tachycardia
(115  bpm),  tachypnoea  (30/min),  no  alteration  in  body
temperature.  Blood  tests  showed  anemia  (6.8  g/dl)  mild  ele-
vation  of  C-Reactive  Protein  (2.8  mg/dl),  increased  white
cells  (40.130  mmc),  Pro-calcitonin  (34  pg/ml),  and  creati-
nine  (1.6  mg/dl),  while  d-dimer  was  inconsistent  and  cardiac
enzymes  were  negative.  The  patient  was  transferred  to
our  ward  on  oxygen  (2  L/min  flow  by  nasal  prongs),  drug
regimen  with  piperacillin/tazobactam  and  prophylactic  lowPlease  cite  this  article  in  press  as:  Fontana  M,  et  al.  Unusua
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molecular  weight  heparin  was  started,  blood  transfusion  was
also  performed.  Due  to  clinical  signs  of  malabsorption,  par-
enteral  nutrition  was  instituted.
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BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)igure  1  Chest-X-Ray  at  admission  in  emergency  room  show-
ng left  lung  parenchymal  consolidation  and  ipsilateral  pleural
ffusion.
Chest  ultrasound  confirmed  a  bilateral  pleural  effusion,
arger  on  the  left,  with  extended  B-lines.  Bilateral  apical
pacities  appeared  at  the  chest-CT  (Fig.  2  upper  panels).
he  whole  body  exams  performed  to  search  for  the  most
ommon  pathogens  (bacteria  and  respiratory  viruses)  were
egative,  and  the  bronchiolo-alveolar  lavage  also  showed  no
ignificant  isolates.
Following  an  initial  clinical  improvement,  the  patient
ondition  deteriorated  with  fever,  tachypnea  and  wors-
ning  of  arterial  hypoxemia  (pO2  40  mmHg  with  2  L/min
xygen)  and  impending  fatigue  of  the  respiratory  system.
eftazidime  was  added,  taking  the  history  of  TW  disease
nto  account.  A  second  chest-CT  documented  the  worsen-
ng  of  the  lung  involvement  (Fig.  2  lower  panels)  so  patient
as  transferred  to  our  respiratory  intensive  care  unit,  oxy-
en  supplementation  was  set  up  to  FiO2  50%  and  antibiotic
egimen  with  cephalosporin  was  started.
The  decision  to  perform  trans-bronchial  biopsies  of  the
ung  parenchymal  consolidations  with  rigid  bronchoscope
as  thus  taken  with  patient  under  sedation  after  intubation;
istology  is  reported  in  Fig.  3.  After  the  procedure,  a  steroidl  effectiveness  of  systemic  steroids  in  Whipple  disease.
7
f  the  respiratory  failure  was  observed  over  the  following
ays.  In  agreement  with  the  infectious  diseases  consultant,
Elsevier Espan˜a, S.L.U. This is an open access article under the CC
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Figure  2  The  first  chest-CT  performed  in  the  ward  demonstrated  bilateral  lung  opacities  with  the  appearance  of  ground-glass  in
the upper  lobes  (see  upper  panel  1  in  different  slices  a  to  c).The  second  chest-CT  performed  after  patient’s  worsening  demonstrated
progression of  the  lung  parenchimal  opacities,  with  consolidations  and  reticolo-nodular  interstitial  thickening  (see  lower  panel  2  in
different slices  a  to  c).
Figure  3  Histologic  specimen  shows  a  non-caseating  granulomatous  inflammation  (left  panel);  the  PAS-stain  was  positive  (right
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Wanel) but  the  PCR  detection  for  Tropheryma  whipplei  was  neg
he  therapy  with  doxycycline  and  hydroxychloroquine  was
tarted.  Finally,  the  patient  was  discharged  without  any  oxy-
en  supplementation  and  steroid  therapy  was  prolonged  and
radually  tapered  during  follow-up.
The  clinical  manifestation  of  Whipple’s  disease  involv-
ng  lung  parenchyma  in  our  patient  follows  other  very  rare
ases  in  the  past  literature.4 As  for  the  other  manifesta-
ions  involving  different  sites,2 diagnosis  is  confirmed  at  thePlease  cite  this  article  in  press  as:  Fontana  M,  et  al.  Unusua
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iopsy  stain  both  by  finding  the  pathogen  with  PCR  method
nd  with  the  PAS  positivity.1
However,  the  case  here  reported  was  atypical:  first,  we
id  not  find  PCR  positivity  for  TW  in  the  biopsy  (despite
t
b
t
s.
he  PAS  positivity);  second,  patient  clinically  improved  once
ystemic  steroid  therapy  was  instituted,  although  steroids
re  not  a  cornerstone  of  disease  treatment.5 Indeed,  since
hen,  patient  continued  to  deteriorate  and  lung  infiltrates
ontinued  to  worsen  despite  antibiotic  treatment  with
ephalosporins,  an  effective  first-line  therapy  in  severe
hipple’s  disease.1
In  the  clinical  history  of  this  patient  we  have  foundl  effectiveness  of  systemic  steroids  in  Whipple  disease.
7
hat  he  had  a  dermatological  manifestation  probably  caused
y  an  immune  reconstitution  syndrome  after  starting  the
herapy  for  Whipple’s  disease.  The  immune  reconstitution
yndrome  in  Whipple  disease  is  extremely  rare  but  reported
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in  the  literature6 with  a  positive  PAS  staining,  but  nega-
tive  PCR  for  TW,  probably  due  to  the  previous  clearance
of  the  pathogen  with  antibiotic  therapy.7 That  was  exactly
what  happened  in  our  patient  with  lung  involvement.  Prob-
ably,  steroid  therapy  might  have  played  a  role  in  limiting
immune  reconstitution.  In  addition,  due  to  his  hematolog-
ical  pathology,  this  patient  was  exposed  to  another  risk  of
a  immune-mediated  complication  i.e.  the  alteration  of  the
monocytes  function  connected  to  an  abnormal  phagocytosis
and  proliferation  of  TW.8 The  fluctuation  in  the  number  of
white  blood  cells  that  we  observed  during  admission  could
have  led  to  the  development  of  an  aberrant  response  to
antibiotics  and  the  elimination  of  the  pathogen.6 At  dis-
charge,  specific  therapy  for  Whipple’s  disease  was  continued
because  of  the  risk  of  relapse,  of  worsening  when  systemic
steroids  or  other  immunosuppressants  are  administered,  and
of  manifestations  due  to  the  immune  reconstitution  when
steroid  therapy  is  suspended  rapidly.1
To  the  best  of  our  knowledge,  this  specific  manifestation
involving  the  lung  has  not  been  previously  described  and  it
sheds  light  on  whether  steroid  therapy  could  be  added  in
some  cases  of  Whipple’s  disease  to  avoid  the  risk  of  further
complications,  such  as  immune-reconstitution  syndrome.
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